Market Overview:
The global colorectal cancer molecular diagnostics market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The market growth is attributed to the increasing incidence of colorectal cancer, technological advancements in molecular diagnostics, and rising demand for personalized medicine. Based on type, the PCR diagnostics segment is expected to account for the largest share of the global colorectal cancer molecular diagnostics market in 2018. This segment is projected to grow at a CAGR of 11.1% from 2018 to 2030 due to the increasing demand for accurate and rapid diagnosis of colorectal cancer. Based on application, hospitals are expected to account for the largest share of the global colorectal cancer molecular diagnostics market in 2018.
Product Definition:
Molecular diagnostics is the use of molecular biology techniques to identify and characterize genes, proteins, and other molecules associated with a particular disease or condition. The importance of colorectal cancer molecular diagnostics lies in its ability to detect early-stage cancers that may not be detectable through traditional methods such as colonoscopy. This allows for more aggressive treatment of these cancers, which can improve patient outcomes.
PCR Diagnostics:
Polymerase Chain Reaction (PCR) is a technique that uses a DNA amplification process. The technology was developed in the early 1980s by Japanese biochemist, Mr. PCR has been an important tool for molecular diagnostics since its inception and has undergone several advancements over the years.
Mass spectrometry Diagnostics:
Mass spectrometry is a branch of analytical chemistry that involves the use of mass-focused instruments to analyze chemical compounds. The technique can separate and identify molecules based on their masses, which makes it an important tool in pharmaceutical research and drug development. In addition, increasing demand for early diagnosis of cancer coupled with rising awareness about the benefits offered by mass spectrometry in colorectal cancer molecular diagnostics market is expected to drive growth during the forecast period.
Application Insights:
The market is segmented by application into hospitals, ambulatory surgical centers, and diagnostic laboratories. The hospital segment dominated the global market in 2017 owing to factors such as increasing prevalence of colorectal cancer and an increase in the number of procedures performed at hospitals compared to other settings. In addition, a rise in government initiatives that aim to improve access to care may also be responsible for driving this growth. For instance, according with new guidelines from NCBI published on January 18th 2018 it has been recommended that people with advanced colorectal cancer should undergo chemotherapy followed by chemoradiation therapy (CRT) instead of surgery alone for better results. This change will help reduce healthcare costs along with improving quality of life for patients suffering from advanced-stage cancers thus contributing towards revenue generation during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, such as Abbott Laboratories, Inc.; Aviva Biosciences; Biocept Inc.; CELGENE CORP; and Roche Molecular Systems. These companies are engaged in R&D activities to improve their products and services for colorectal cancer molecular diagnostics. Moreover, these entities are also involved in strategic initiatives such as collaborations and acquisitions that will help them expand their reach across this region. For instance, In January 2018, Gen-y Development Partners LLC invested USD X million for a majority stake acquisition of Colorectal Diagnostic Solutions LLC’s assets including intellectual property (patents), equipment (flow Cytometers & Automated Analyzers), personnel & client list etc.
Growth Factors:
- Increasing incidence of colorectal cancer
- Rising demand for early diagnosis and treatment of colorectal cancer
- Growing awareness about the benefits of molecular diagnostics for colorectal cancer
- Technological advancements in molecular diagnostics for colorectal cancer
- Increasing funding for research and development in molecular diagnostics for colorectal cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Colorectal Cancer Molecular Diagnostics Market Research Report
By Type
PCR Diagnostics, Mass spectrometry Diagnostics, Others, Colorectal Cancer Molecular Diagnostic
By Application
Hospitals, Ambulatory Surgical Centers, Diagnostic Laboratories
By Companies
Agilent, Hologic, Qiagen, Roche, Bayer, Abbott, Grifols, Danaher, Siemens, BD, Biomérieux, Sysmex, Colorectal Cancer Molecular Diagnostic
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Colorectal Cancer Molecular Diagnostics Market Report Segments:
The global Colorectal Cancer Molecular Diagnostics market is segmented on the basis of:
Types
PCR Diagnostics, Mass spectrometry Diagnostics, Others, Colorectal Cancer Molecular Diagnostic
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Diagnostic Laboratories
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Agilent
- Hologic
- Qiagen
- Roche
- Bayer
- Abbott
- Grifols
- Danaher
- Siemens
- BD
- Biomérieux
- Sysmex
- Colorectal Cancer Molecular Diagnostic
Highlights of The Colorectal Cancer Molecular Diagnostics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- PCR Diagnostics
- Mass spectrometry Diagnostics
- Others
- Colorectal Cancer Molecular Diagnostic
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Diagnostic Laboratories
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Colorectal Cancer Molecular Diagnostics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Molecular diagnostics is a field of medicine that uses molecular techniques to diagnose diseases. Molecular diagnostics can be used to identify the cause of a disease, find out if someone has the disease, and determine how severe it is. Molecular diagnostics can also help doctors treat patients with diseases.
Some of the major players in the colorectal cancer molecular diagnostics market are Agilent, Hologic, Qiagen, Roche, Bayer, Abbott, Grifols, Danaher, Siemens, BD, BiomƒÂ©rieux, Sysmex, Colorectal Cancer Molecular Diagnostic.
The colorectal cancer molecular diagnostics market is expected to register a CAGR of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Colorectal Cancer Molecular Diagnostics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Colorectal Cancer Molecular Diagnostics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Colorectal Cancer Molecular Diagnostics Market - Supply Chain
4.5. Global Colorectal Cancer Molecular Diagnostics Market Forecast
4.5.1. Colorectal Cancer Molecular Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Colorectal Cancer Molecular Diagnostics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Colorectal Cancer Molecular Diagnostics Market Absolute $ Opportunity
5. Global Colorectal Cancer Molecular Diagnostics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Type
5.3.1. PCR Diagnostics
5.3.2. Mass spectrometry Diagnostics
5.3.3. Others
5.3.4. Colorectal Cancer Molecular Diagnostic
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Colorectal Cancer Molecular Diagnostics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Ambulatory Surgical Centers
6.3.3. Diagnostic Laboratories
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Colorectal Cancer Molecular Diagnostics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Colorectal Cancer Molecular Diagnostics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Colorectal Cancer Molecular Diagnostics Demand Share Forecast, 2019-2026
9. North America Colorectal Cancer Molecular Diagnostics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Ambulatory Surgical Centers
9.4.3. Diagnostic Laboratories
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Type
9.7.1. PCR Diagnostics
9.7.2. Mass spectrometry Diagnostics
9.7.3. Others
9.7.4. Colorectal Cancer Molecular Diagnostic
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Colorectal Cancer Molecular Diagnostics Demand Share Forecast, 2019-2026
10. Latin America Colorectal Cancer Molecular Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers
10.4.3. Diagnostic Laboratories
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Type
10.7.1. PCR Diagnostics
10.7.2. Mass spectrometry Diagnostics
10.7.3. Others
10.7.4. Colorectal Cancer Molecular Diagnostic
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Colorectal Cancer Molecular Diagnostics Demand Share Forecast, 2019-2026
11. Europe Colorectal Cancer Molecular Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Ambulatory Surgical Centers
11.4.3. Diagnostic Laboratories
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Colorectal Cancer Molecular Diagnostics Market Sze and Volume Forecast by Type
11.7.1. PCR Diagnostics
11.7.2. Mass spectrometry Diagnostics
11.7.3. Others
11.7.4. Colorectal Cancer Molecular Diagnostic
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Colorectal Cancer Molecular Diagnostics Demand Share, 2019-2026
12. Asia Pacific Colorectal Cancer Molecular Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Ambulatory Surgical Centers
12.4.3. Diagnostic Laboratories
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Type
12.7.1. PCR Diagnostics
12.7.2. Mass spectrometry Diagnostics
12.7.3. Others
12.7.4. Colorectal Cancer Molecular Diagnostic
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Colorectal Cancer Molecular Diagnostics Demand Share, 2019-2026
13. Middle East & Africa Colorectal Cancer Molecular Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Centers
13.4.3. Diagnostic Laboratories
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Colorectal Cancer Molecular Diagnostics Market Size and Volume Forecast by Type
13.7.1. PCR Diagnostics
13.7.2. Mass spectrometry Diagnostics
13.7.3. Others
13.7.4. Colorectal Cancer Molecular Diagnostic
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Colorectal Cancer Molecular Diagnostics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Colorectal Cancer Molecular Diagnostics Market: Market Share Analysis
14.2. Colorectal Cancer Molecular Diagnostics Distributors and Customers
14.3. Colorectal Cancer Molecular Diagnostics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Agilent
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Hologic
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Qiagen
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Roche
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bayer
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Abbott
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Grifols
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Danaher
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Siemens
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. BD
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Biomérieux
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Sysmex
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Colorectal Cancer Molecular Diagnostic
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
